Hi [[ session.user.profile.firstName ]]

Battle of the ALKs: ALK IHC vs. ISH in treatment of ALK-positive advanced NSCLC

Join Dr. Ed Schuuring and Dr. Harry Groen, University Medical Center Groningen, The Netherlands, to explore the role of immunohistochemistry (IHC) in the assessment of ALK rearrangements in non-small cell lung cancer (NSCLC), with a focus on the binary algorithm and comparison with fluorescence in situ hybridization (FISH). Clinical implications for ALK IHC vs. FISH and treatment options for ALK inhibitors will be discussed including side effects and overall as well as intracranial efficacy.
Recorded Feb 28 2019 56 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Prof Dr EMD (Ed) Schuuring & Prof Dr HJM (Harry) Groen
Presentation preview: Battle of the ALKs: ALK IHC vs. ISH in treatment of ALK-positive advanced NSCLC

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
CDx Insights
CDx Insights is a series brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Battle of the ALKs: ALK IHC vs. ISH in treatment of ALK-positive advanced NSCLC
  • Live at: Feb 28 2019 3:00 pm
  • Presented by: Prof Dr EMD (Ed) Schuuring & Prof Dr HJM (Harry) Groen
  • From:
Your email has been sent.
or close